Status:

COMPLETED

Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints

Lead Sponsor:

Beni-Suef University

Conditions:

Breast Cancer

Eligibility:

All Genders

18-85 years

Phase:

PHASE2

Brief Summary

To compare evaluating Clinical outcomes for patients treated with with or without breast cancer patients comorbidity for sever COVID-19 infection in breast cancer patients versus non cancer patients a...

Detailed Description

Cancer patients considered to be one of the least population that can be considered lucky during COVID 19 pandemic attributed that to long term treatment with chemotherapy, immunosuppression and multi...

Eligibility Criteria

Inclusion

  • patients admitted to ICU with or without breast cancer (non-metastatic) comorbidity
  • age 18-85 years' old
  • moderate to sever confirmed COVID 19 infection through PCR and CT
  • male or female
  • confirmed Covid-19 by PCR
  • Requiring ICU admission
  • WITH evidence of severe COVID-19 (at least 2 of the following):
  • Fever \> 38C within 72 hours
  • Pulmonary infiltrate on chest X ray /ground glass opacity
  • Need for supplemental O2 to maintain saturation \> 92%
  • AND at least 1 of the following:
  • Ferritin \> 500 ng/ml
  • CRP \> 50 mg/L
  • LDH \>250 U/L
  • D-dimer \> 1000 ng/mL
  • all patient assigned informed consent

Exclusion

  • above 85 years' old
  • metatastic breast cancer
  • autoimmune disease patients
  • Unable to provide verbal informed consent
  • preganncy
  • Subjects between the ages of 70 and 75 will be excluded if they have NYHA Class III/IV heart failure
  • Active TB
  • Receipt of IV tocilizumab for the treatment of a non-COVID condition within 3 weeks of the first COVID symptom
  • History of hypersensitivity to tocilizumab 7. ANC \<500, Platelets \<50,000\* 8. AST/ALT \> 5X ULN

Key Trial Info

Start Date :

April 26 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 26 2022

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04871854

Start Date

April 26 2021

End Date

August 26 2022

Last Update

November 1 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

ALsafwa specialized hospital

Al Fayyum, Egypt, 11454